Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Colon and Rectal Surgery
  •  Pediatric Surgery
  •  Plastic Surgery
  •  Bariatric Surgery
  •  Endocrine Surgery
  •  Urology
  •  Cardiovascular Surgery
  •  Oral and Maxillofacial Surgery

Abstract

Citation: Clin Surg. 2021;6(1):3212.Research Article | Open Access

A Prospective Study on the Role of Centchroman in Regression of Fibroadenoma

Navdeep Kumar Singla , Ruby Bhatia , Renu Verma and Suresh Kumar Bhatia

Department of General Surgery, GMC Patiala, Punjab, India Department of Obstetrics and Gynecology, GMC Patiala, Punjab, India

*Correspondance to: Renu Verma 

 PDF  Full Text DOI: 10.25107/2474-1647.3212

Abstract

Fibroadenoma commonly present as painless breast lump in young girls. Nearly 10% to 15% regress spontaneously over the period of 6 to 60 months, rest are managed surgically. Centchroman (Saheli), a novel non-steroidal, selective anti-estrogen has been used for the treatment of mastalgia and its effectiveness in the treatment of fibroadenoma is being tested in the ongoing trials. Patients and Methods: We studied the role of Centchroman in regression of fibroadenoma. A total of 60 patients between 15 to 35 years of age with painless lump breast of size 2 cm to 5 cm confirmed as fibroadenoma by FNAC were included in the study. Detailed patient?s characteristics, clinical history, physical examination (for size in 2 dimensions), ultrasound findings (for size in 3 dimensions) were assessed. All participants included in the study were given tablet Centchroman (Saheli) 30 mg thrice weekly orally for 3 months. Size of Fibroadenoma was reassessed clinically for size in two dimensions and ultrasonologically for size in three dimensions at 4 weeks and 3 months of starting of therapy. Conclusion: Out of 60 patients, 18 patients (30%) had complete response, 40 patients (66.66%) showed a decrease in the size of fibroadenoma and only 2 patients (3.33%) had no response to this therapy. None showed an increase in size. It may prove to be the most effective modality for the treatment of small sized fibroadenoma breast especially in unmarried girls with minimal side effects. Ultrasonology may be relied upon for follow up measurements since it is more accurate in measuring the dimensions.

Keywords

Fibroadenoma; Centchroman; Saheli; Non-steroidal; Anti-estrogen; Ultrasonology

Cite the article

Singla NK, Bhatia R, Verma R, Bhatia SK. A Prospective Study on the Role of Centchroman in Regression of Fibroadenoma. Clin Surg. 2021; 6: 3212..

Search Our Journal

Journal Indexed In

Articles in PubMed

Mesh Sprayer Device with Liquefied Mesh Delivery System: Proposed Alternative for Currently Available Meshes in Hernia Repair and Supplement to Abdominal Closure
 PubMed  PMC  PDF  Full Text
RAF Kinase Inhibitory Protein Expression and Phosphorylation Profiles in Oral Cancers
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

How to Choose the Site of Injection for Sentinel Lymph Node Mapping for Endometrial Cancer
 PDF  Full Text
Ultra-Fresh Osteochondral Allograft Transplantation Supported by Artificial Intelligence Algorithms - Case Report of a 14-Year-Old Patient
 Abstract  PDF  Full Text
View More...